Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Abstract Background Circulating tumor cells (CTCs) are prognostic in patients with advanced breast cancer (ABC). However, no data exist about their use in patients treated with palbociclib. We analyzed the prognostic role of CTC counts in patients enrolled in the cTREnd study, a pre-planned translat...

Full description

Bibliographic Details
Main Authors: Francesca Galardi, Francesca De Luca, Chiara Biagioni, Ilenia Migliaccio, Giuseppe Curigliano, Alessandro M. Minisini, Martina Bonechi, Erica Moretti, Emanuela Risi, Amelia McCartney, Matteo Benelli, Dario Romagnoli, Silvia Cappadona, Stefano Gabellini, Cristina Guarducci, Valerio Conti, Laura Biganzoli, Angelo Di Leo, Luca Malorni
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Breast Cancer Research
Subjects:
Liquid biopsy
CTCs
Luminal breast cancer
Metastatic
Palbociclib
CDK4/6 inhibitor
Online Access:https://doi.org/10.1186/s13058-021-01415-w

Internet

https://doi.org/10.1186/s13058-021-01415-w

Similar Items